Global Multi Cancer Early Detection Market Size study, By Type (Liquid Biopsy, Gene Panel, LDT, & Others), By End-User (Hospitals, Diagnostic Laboratories, Others), and Regional Forecasts 2022-2028

Global Multi Cancer Early Detection Market Size study, By Type (Liquid Biopsy, Gene Panel, LDT, & Others), By End-User (Hospitals, Diagnostic Laboratories, Others), and Regional Forecasts 2022-2028

Global Multi Cancer Early Detection Market is valued at approximately USD 791.58 million in 2021 and is anticipated to grow with a healthy growth rate of more than 15.0% over the forecast period 2022-2028. Multi-cancer detection (MCD) measure biological signals that may be released by cancer cells in bodily fluids. These indicators are frequently referred to as tumour markers or biomarkers. MCD assays are being created to simultaneously screen for malignancies in multiple organ sites. The market for multi cancer early detection (MCED) is anticipated to expand as a result of factors such as the rising incidence of cancer and the government's increased emphasis on cancer early detection. According to the WHO, cancer will account for about 10 million deaths in 2020, or almost one in every six deaths worldwide. One-third of cancer-related deaths are caused by variables such as smoking, having a high body mass index, drinking, being obese, and having high cholesterol. Because early cancer detection can increase patient survival and save treatment costs, there is a rising business opportunity. According to estimates from the International Agency for Research on Cancer (IARC), globally, there were 17.0 million new instances of cancer and 9.5 million cancer-related deaths in 2018. It is estimated to increase the worldwide burden of cancer to 27.5 million new cases by 2040. Also, need to develop diagnostic options that can detect cancer at an early stage and increased dependence of hospitals on diagnostic laboratories for testing and evaluation are anticipated to act as catalyzing factors for the market demand during the forecast period. However, collection of adequate safety and efficacy data for regulatory approval may impede the growth of the market over the forecast period of 2022-2028.

The key regions considered for the global Multi Cancer Early Detection market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. Europe is the leading region across the world in terms of market share owing to the increased funding in R&D and the increased prevalence of cancer in the region. Whereas, North America is anticipated to exhibit a significant growth rate over the forecast period 2022-2028. Factors such as the rising prevalence of cancer, and rising technological advancement in the region are fueling the growth of market.

Major market players included in this report are:
Grail, LLC (Illumina, Inc.)
Illumina, Inc.
Exact Sciences Corporation.
Foundation Medicine, Inc.
AnchorDx
Guardant Health, Inc.
Burning Rock Biotech Limited
GENECAST
Laboratory for Advanced Medicine, Inc.
Singlera Genomics Inc

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Type:
Liquid Biopsy
Gene Panel, LDT, & Others
By End-User:
Hospitals
Diagnostic Laboratories
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Multi Cancer Early Detection Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors


Companies Mentioned

Grail, LLC (Illumina, Inc.)
Illumina, Inc.
Exact Sciences Corporation.
Foundation Medicine, Inc.
AnchorDx
Guardant Health, Inc.
Burning Rock Biotech Limited
GENECAST
Laboratory for Advanced Medicine, Inc.
Singlera Genomics Inc

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.